Zentalis (ZNTL) with unusual buy of 1000 April $50/$70 call spreads for $4.50 this morning, started Overweight at Wells Fargo this morning. ZNTL set to present data at AACR Meeting with five presentations planned including first cut of data from Phase 1b combination study in advanced ovarian cancer, in addition to presenting additional data from the USC expansion cohort of the Phase 1 monotherapy trial. To date, ZN-c3 has demonstrated durable clinical activity and good tolerability in varying indications, and to further explore this candidate’s potential as investigate its synergy with internal and external combinations